NCT01522547View on ClinicalTrials.gov

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

October 1, 2012

Study Completion Date

December 1, 2013

Conditions
Anemia, Sickle Cell
Interventions
DRUG

pomalidomide

Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Trial Locations (1)

48201-2097

Karmanos Cancer Institute, Detroit

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY